Why Do I See Rapid Resolution With CONVENIA® (cefovecin sodium)?

A hypothesis based on learnings from human and veterinary medicine.

Cytokines protein messengers

- Cause itch in atopic dermatitis
- Cause inflammation in skin infections

CONVENIA works fast

CONVENIA is unrelenting for 14 days

Hits Hard. Hits Fast.
Within the first 24 hours, CONVENIA reaches free concentrations of >14x the MIC90 of Staph. intermedius in the tissue.

CONVENIA vs Oral Medications
When antibiotic concentration drops below the MIC90, bacteria are no longer inhibited and the effect on the inflammatory process is questionable.

IMPORTANT SAFETY INFORMATION: People with known hypersensitivity to penicillin or cephalosporins should avoid exposure to CONVENIA. Do not use in dogs or cats with a history of allergic reactions to penicillins or cephalosporins. Side effects for both dogs and cats include vomiting, diarrhea, decreased appetite/anorexia and lethargy. See full Prescribing Information, attached.

CONVENIA is indicated for the treatment of skin infections (secondary superficial pyoderma, abscesses and wounds) in dogs caused by susceptible strains of Staphylococcus intermedius and Streptococcus canis (Group G). CONVENIA is indicated for the treatment of skin infections (wounds and abscesses) in cats caused by susceptible strains of Pasteurella multocida.


All trademarks are the property of Zoetis Inc., its affiliates and/or its licensors.
©2015 Zoetis Inc. All rights reserved. August 2015. AIF-00305
See how quickly clinical signs of skin infections can begin to improve with CONVENIA.*†

Not weeks. Not days. Hours.

*Two-year-old American Staffordshire terrier with acute moist dermatitis treated only with CONVENIA® (cefovecin sodium) 8 mg/kg.

†Case included an initial skin cleansing with a dilute topical antiseptic.

For more information, go to convenia.com or talk to your Zoetis™ representative.

IMPORTANT SAFETY INFORMATION: CONVENIA is not for use in dogs or cats with a history of allergic reactions to penicillins or cephalosporins. Similar to other cephalosporins, side effects for both dogs and cats include vomiting, diarrhea, decreased appetite/anorexia and lethargy. The safety of CONVENIA has not been determined in lactating or breeding animals. For more information, please see Full Prescribing Information.
One and done.

In a U.S. efficacy study, 86% of dogs needed only one injection to resolve their skin infection.¹

Recommend CONVENIA® (cefovecin sodium) for first-time resolution of bacterial skin infections.

convenia.com

Three-year-old mixed breed diagnosed with facial moist dermatitis treated with CONVENIA 8 mg/kg

IMPORTANT SAFETY INFORMATION: People with known hypersensitivity to penicillin or cephalosporins should avoid exposure to CONVENIA. Do not use in dogs or cats with a history of allergic reactions to penicillins or cephalosporins. Side effects for both dogs and cats include vomiting, diarrhea, decreased appetite/anorexia and lethargy. See full Prescribing Information, attached.


All trademarks are the property of Zoetis Inc., its affiliates and/or its licensees.

©2015 Zoetis Inc. All rights reserved. August 2015. AIF-00305
Antimicrobial Activity for Subcutaneous Injections in Dogs and Cats Only

CONVENIA is a cephalosporin antibiotic. Like other cephalosporins, CONVENIA exerts its inhibitory effect by interfering with bacterial cell wall synthesis. CONVENIA is a semi-synthetic broad-spectrum antibacterial agent from the third-generation cephalosporin class of chemotherapeutic agents. CONVENIA is active against a wide range of susceptible bacterial pathogens. In vitro, the MIC90 of CONVENIA for susceptible strains is 0.008 μg/mL. CONVENIA is comparable to other cephalosporins, but due to the high affinity protein binding, the in vivo free concentration of cefovecin does not reach the MIC90 for most microbes. For E. coli (0.012 μg/mL) CONVENIA is not active against Pseudomonas spp. or enterococci.

**Dogs**

The minimum inhibitory concentration (MIC) values for cefovecin against label claim pathogens were determined at the University of Tennessee. The MIC values for cefovecin against the pathogens are presented in Table 5. All MICs were determined in accordance with the CLSI standards.

**Cats**

The MIC values for cefovecin against Pasteurella multocida isolated from skin infections were determined at the University of Tennessee. The MIC values for cefovecin against the pathogens are presented in Table 5. All MICs were determined in accordance with the CLSI standards.

**EFFECTIVENESS:**

In a double-masked, 1:1 randomized canine field study conducted in the United States, the effectiveness of CONVENIA was compared to the control antibiotic. In this study, 296 dogs with susceptible primary sepsis, abscesses, or infected wounds were treated with an average of approximately 5 mg (1.2 mg/kg) body weight or with an active control antibiotic (tetracycline), administered twice daily for 14 days. In this study, dogs could receive a total of up to 14 days of active treatment. At the 30th enrolled day, 22 of 76 dogs received 2 treatments of CONVENIA and 23 of 63 dogs received 2 courses of tetracycline. The primary endpoints of outcome effectiveness for CONVENIA and of the 163 enrolled cases were evaluated for effectiveness of the active control antibiotic, administered either once or twice daily, and for microbiologic and clinical success rates obtained 28 days after the initiation of the final course of therapy. The clinical success rates were obtained 28 days after the initiation of Therapy and are presented in Table 8.

**ANIMAL SAFETY:**

CONVENIA administered to healthy 4-month-old dogs at doses of 12 mg/kg (3.6 mg/kg body weight) and with an oral active control antibiotic (tetracycline) administered twice daily for 14 days. Cefovecin is a cephalosporin antibiotic (i.e., metabolized by β-lactamase enzymes). Table 8 contains the mean and standard deviation of the neutrophil alkaline phosphatase (NAP) activity in the 4-month-old dogs of CONVENIA’s safety study. All MICs were determined in accordance with the CLSI standards.

**STORAGE INFORMATION:**

CONVENIA is a sterile, lyophilized cake. Distributed by Zoetis Inc. at 1-888-963-8471. It is a cephalosporin antibiotic. Like other cephalosporins, CONVENIA exerts its inhibitory effect by interfering with bacterial cell wall synthesis. CONVENIA is a semi-synthetic broad-spectrum antibacterial agent from the third-generation cephalosporin class of chemotherapeutic agents. CONVENIA is active against a wide range of susceptible bacterial pathogens. In vitro, the MIC90 of CONVENIA for susceptible strains is 0.008 μg/mL. CONVENIA is comparable to other cephalosporins, but due to the high affinity protein binding, the in vivo free concentration of cefovecin does not reach the MIC90 for most microbes. For E. coli (0.012 μg/mL) CONVENIA is not active against Pseudomonas spp. or enterococci.

**Dogs**

The minimum inhibitory concentration (MIC) values for cefovecin against label claim pathogens were determined at the University of Tennessee. The MIC values for cefovecin against the pathogens are presented in Table 5. All MICs were determined in accordance with the CLSI standards.

**Cats**

The MIC values for cefovecin against Pasteurella multocida isolated from skin infections were determined at the University of Tennessee. The MIC values for cefovecin against the pathogens are presented in Table 5. All MICs were determined in accordance with the CLSI standards.

**EFFECTIVENESS:**

In a double-masked, 1:1 randomized canine field study conducted in the United States, the effectiveness of CONVENIA was compared to the control antibiotic. In this study, 296 dogs with susceptible primary sepsis, abscesses, or infected wounds were treated with an average of approximately 5 mg (1.2 mg/kg) body weight or with an active control antibiotic (tetracycline), administered twice daily for 14 days. In this study, dogs could receive a total of up to 14 days of active treatment. At the 30th enrolled day, 22 of 76 dogs received 2 treatments of CONVENIA and 23 of 63 dogs received 2 courses of tetracycline. The primary endpoints of outcome effectiveness for CONVENIA and of the 163 enrolled cases were evaluated for effectiveness of the active control antibiotic, administered either once or twice daily, and for microbiologic and clinical success rates obtained 28 days after the initiation of the final course of therapy. The clinical success rates were obtained 28 days after the initiation of Therapy and are presented in Table 8.

**ANIMAL SAFETY:**

CONVENIA administered to healthy 4-month-old dogs at doses of 12 mg/kg (3.6 mg/kg body weight) and with an oral active control antibiotic (tetracycline) administered twice daily for 14 days. Cefovecin is a cephalosporin antibiotic (i.e., metabolized by β-lactamase enzymes). Table 8 contains the mean and standard deviation of the neutrophil alkaline phosphatase (NAP) activity in the 4-month-old dogs of CONVENIA’s safety study. All MICs were determined in accordance with the CLSI standards.

**STORAGE INFORMATION:**

CONVENIA is a sterile, lyophilized cake. Distributed by Zoetis Inc. at 1-888-963-8471. It is a cephalosporin antibiotic. Like other cephalosporins, CONVENIA exerts its inhibitory effect by interfering with bacterial cell wall synthesis. CONVENIA is a semi-synthetic broad-spectrum antibacterial agent from the third-generation cephalosporin class of chemotherapeutic agents. CONVENIA is active against a wide range of susceptible bacterial pathogens. In vitro, the MIC90 of CONVENIA for susceptible strains is 0.008 μg/mL. CONVENIA is comparable to other cephalosporins, but due to the high affinity protein binding, the in vivo free concentration of cefovecin does not reach the MIC90 for most microbes. For E. coli (0.012 μg/mL) CONVENIA is not active against Pseudomonas spp. or enterococci.

**Dogs**

The minimum inhibitory concentration (MIC) values for cefovecin against label claim pathogens were determined at the University of Tennessee. The MIC values for cefovecin against the pathogens are presented in Table 5. All MICs were determined in accordance with the CLSI standards.

**Cats**

The MIC values for cefovecin against Pasteurella multocida isolated from skin infections were determined at the University of Tennessee. The MIC values for cefovecin against the pathogens are presented in Table 5. All MICs were determined in accordance with the CLSI standards.

**EFFECTIVENESS:**

In a double-masked, 1:1 randomized canine field study conducted in the United States, the effectiveness of CONVENIA was compared to the control antibiotic. In this study, 296 dogs with susceptible primary sepsis, abscesses, or infected wounds were treated with an average of approximately 5 mg (1.2 mg/kg) body weight or with an active control antibiotic (tetracycline), administered twice daily for 14 days. In this study, dogs could receive a total of up to 14 days of active treatment. At the 30th enrolled day, 22 of 76 dogs received 2 treatments of CONVENIA and 23 of 63 dogs received 2 courses of tetracycline. The primary endpoints of outcome effectiveness for CONVENIA and of the 163 enrolled cases were evaluated for effectiveness of the active control antibiotic, administered either once or twice daily, and for microbiologic and clinical success rates obtained 28 days after the initiation of the final course of therapy. The clinical success rates were obtained 28 days after the initiation of Therapy and are presented in Table 8.